San Diego, CA -- (SBWIRE) -- 01/02/2018 -- Novavax, Inc is under investigation over possible securities laws violations in connection with certain financial statements. The investigation was announced for investors in NASDAQ:NVAX shares.

Investors who purchased shares of Novavax, Inc. (NASDAQ:NVAX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on whether certain statements by Novavax, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Gaithersburg, MD based Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.
Novavax, Inc. reported that its annual Total Revenue declined from $36.25 million in 2015 to $15.35 million in 2016 and that its Net Loss increased from $156.94 million in 2015 to $279.97 million in 2016.

In November 2017, Novavax, Inc. projected a year-end release for top-line data from the Company's Phase 1/2 clinical trial of its NanoFlu Vaccine.

Then, on December 19, 2017, Novavax, Inc. announced that a "complete package" will not be completed and released until February 2018. Novavax, Inc. advised investors that "the wild-type viruses necessary to assess immunogenicity of the vaccines to circulating strains have been difficult to obtain, grow and maintain genetic stability."

Those who purchased shares of Novavax, Inc. (NASDAQ:NVAX) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com